Saroja Pharma In

A loyal extensive customer base;

Procurement of high quality pharmaceutical raw materials to be made available to our esteemed clients;

Extensive wide loyal purchase (Manufacturer) base;

Well trained professional staff to deliver the best in terms of resource procurements, documentation and time saving fast logistics;

Insurance of materials at all destinations (Loading, unloading, warehouse and in transit) ensuring safe and hasslefree dispatch of consignment globally;

The process of implementation at every point in accordance to government rules, regulations, requirements along with best global practices;

Fast and efficient decision-making approach of management with open approach to staff insights.

The property used by the Company for the operation purpose of its storage is not owned by it. Any termination of the relevant lease agreement or rent agreement in connection with such property or its failure to renew the same could adversely affect the Company operations.

The Company business is substantially dependent on its key customers from whom we derive a significant portion of its revenues. The loss of any significant clients may have a material and adverse effect on its business and results of operations.

The Company Domestic Sales is dependent on Top 5 States of India, the loss of any significant clients in this states may have a material and adverse effect on its business and results of operations.

The Company is dependent on few numbers of suppliers for purchase of product. Loss of any of this large Suppliers may affect its business and results of operations.

The Company will continue to be controlled by its Promoters and certain related entities after the completion of the Issue.

The company has to update the name of its company in some of the statutory approvals and certificates due to the conversion of the Company in to Public Limited Company.

The Company business requires it to obtain and renew certain registrations, licenses and permits from government and regulatory authorities and the failure to obtain and renew them in a timely manner may adversely affect the Company business operations.

There are no long term supply agreements with its vendors/suppliers. The company Business may be adversely affected if there is any disruption in the trading material supply or due to non- availability of trading material.

The company business is dependent on its continuing relationships with its clients, with whom the company has not entered into long term arrangements.

The COVID-19 pandemic has had, and is expected to have, a material adverse effect on the company business, financial condition, results of operations and cash flows.

In the event of any disruption in the supply or the non-availability of material in the required quantity and of required quality from alternate source, the supply schedule to its clients may be adversely be affected impacting the sales and profitability of the Company.

Some of the trading items are hazardous in nature. In the event of any accidents involving any such hazardous materials and substances, the Company may be held liable for subsequent damages and litigations.

The Company had negative cash flow in recent fiscals, details of which are given below. Sustained negative cash flow could adversely impact its business, financial condition and results of operations.

The company insurance coverage may not adequately protect it against certain operating risks and this may have an adverse effect on the results of its business.

The company is dependent on third party transportation providers for delivery of trading goods and materials to it from its suppliers and delivery of trading goods and materials to its clients. Any failure on part of such service providers to meet their obligations could have a material adverse effect on the company business, financial condition and results of operation.

Failure to manage its stocks could have an adverse effect on the company net sales, profitability, cash flow and liquidity.

The company could be exposed to risks arising from misconduct, fraud and trading errors by its employees and Business Associates.

The company is subject Foreign Exchange Rate fluctuation and strict compliance of The Foreign Exchange Regulations Act, 1973 (FERA) and the provisions of FEMA.

The company operate in a highly competitive industry. Any inability to compete effectively may lead to a lower market share or reduced operating margins.

Conditions and restrictions imposed on us by the agreements governing its indebtedness could adversely affect the company ability to operate the company business.

Excessive dependence on any key managerial personnel for the project for which the issue is being made.

The company Promoters, Directors and Key Managerial Personnel may have interest in the Company, other than reimbursement of expenses incurred or remuneration.

The company ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements, capital expenditure and restrictive covenants in its financing arrangements.

In addition to normal remuneration, other benefits and reimbursement of expenses to the company Promoters and Directors; they are interested to the extent of their shareholding and dividend entitlement thereon in the Company and for the transactions entered into between the Company and themselves.

The Company has in the past entered into related party transactions and may continue to do so in the future and its cannot assure you that the company could not have achieved more favourable terms if such transactions had not been entered into with related parties. And will not have an adverse effect on its financial conditions and result of operations.

Strikes, work stoppages or increased wage demands by the company employees or any other kind of disputes with its employees/workmen in future could adversely affect its business and results of operations.

Compliance with and changes in safety, health and environmental laws and various labours, workplace and related laws and regulations impose additional costs and may increase its compliance costs and a such adversely affect the company results of operations and its financial condition.

The company management has discretion in how it may use the proceeds of the Issue. Any variation in the utilisation of its Net Proceeds would be subject to certain compliance requirements, including prior shareholders` approval.

The company Object has not been appraised by any Bank or Financial Institution. Any significant deviation in the Object could adversely impact its operations and sustainability in absence of any independent monitoring agency.

There is no monitoring agency appointed by the Company and the deployment of funds are at the discretion of its Management and its Board of Directors, though it shall be monitored by its Audit Committee.

The average cost of acquisition of Equity shares by its Promoters is lower than the Issue price. the company promoters average cost of acquisition of Equity shares in its lower than the Issue Price of Equity shares.

The company require high working capital for its smooth day to day operations of business and any discontinuance or its inability to acquire adequate working capital timely and on favorable terms at a future date, may have an adverse effect on its operations, profitability and growth prospects.

The company success largely depends on its Board and Key Managerial Personnel and its ability to attract and retain them. Any loss of the director and key managerial personnel could adversely affect its business, operations and financial condition.

The company have not made any alternate arrangements for meeting its capital requirements for the Objects of the issue. Further its have not identified any alternate source of financing the "Objects of the Issue". Any shortfall in raising/ meeting the same could adversely affect its growth plans, operations and financial performance.

Certain information contained in this Draft Prospectus is based on management estimates and the company cannot assure you of the completeness or accuracy of the data.

Pharma Industry information included in this Draft Prospectus has been derived from industry reports commissioned by it for such purpose. There can be no assurance that such third-party statistical, financial and other industry information is either complete or accurate.